Last reviewed · How we verify
PF-0704091 + Fulvestrant (post CDK4/6) (pf-0704091-fulvestrant-post-cdk4-6)
PF-0704091 + Fulvestrant (post CDK4/6) (generic name: pf-0704091-fulvestrant-post-cdk4-6) is a drug developed by Pfizer Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | pf-0704091-fulvestrant-post-cdk4-6 |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 2 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-0704091 + Fulvestrant (post CDK4/6) CI brief — competitive landscape report
- PF-0704091 + Fulvestrant (post CDK4/6) updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about PF-0704091 + Fulvestrant (post CDK4/6)
What is PF-0704091 + Fulvestrant (post CDK4/6)?
PF-0704091 + Fulvestrant (post CDK4/6) (pf-0704091-fulvestrant-post-cdk4-6) is a pharmaceutical drug developed by Pfizer Inc..
Who makes PF-0704091 + Fulvestrant (post CDK4/6)?
PF-0704091 + Fulvestrant (post CDK4/6) is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).
What is the generic name of PF-0704091 + Fulvestrant (post CDK4/6)?
pf-0704091-fulvestrant-post-cdk4-6 is the generic (nonproprietary) name of PF-0704091 + Fulvestrant (post CDK4/6).
What development phase is PF-0704091 + Fulvestrant (post CDK4/6) in?
PF-0704091 + Fulvestrant (post CDK4/6) is in Phase 2.